<DOC>
	<DOCNO>NCT01979744</DOCNO>
	<brief_summary>Although first generation DES reduce instent restenosis , still remain unsolved problem stent thrombosis restenosis era DES . Second generation DES develop improve biocompatibility stent coat focus polymer compare first generation DES , second generation stent show well outcome compare first generation DES . On hand , third generation DES , refinement DES involve flexible stent platform . Promus ElementTM ( Everolimus elute stent , Boston Scientific , Nastick , MA ) Resolute Integrity® ( Zotarolimus elute stent , Medtronic Vascular , Santa Rosa , CA ) third generation drug elute stent design increase flexibility . In previous randomize controlled study , stent show least non-inferior angiographic clinical outcome compare second generation DES . However , lack data comparison angiographic clinical outcome Promus ElementTM Resolute Integrity® . IVUS one widely use intracoronary imaging device provide reproducible accurate information coronary anatomy angiography current practice.8 Optimal stent expansion assess intravascular ultrasound ( IVUS ) report important factor prevent stent thrombosis restenosis.9 Accordingly , many study evaluate procedural clinical benefit IVUS guide angioplasty . However , The clinical benefit IVUS-guided angioplasty stent implantation still controversy . In previous study , IVUS-guided stent implantation show positive negative beneficial effect clinical outcome accord study subject . However , stent use previous study less useful current practice cardiology lack data 3rd generation DES , different stent profile outcomes predecessor . Thus would perform prospective randomize study order compare efficacy IVUS-guided angioplasty conventional angioplasty-guided procedure long coronary lesion . Our main hypothesis IVUS-guided 3rd generation DES implantation long coronary lesion would better clinical outcome compare conventional angiography-guided strategy . We also intend assess clinical outcome Promus ElementTM Resolute Integrity® implantation .</brief_summary>
	<brief_title>Intravascular ULTrasound Guided Versus Conventional Angiography Guided Strategy Deploy Zotarolimus Everolimus Eluting Third Generation Stents Long Coronary Artery Lesions : ULTRA-ZET Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients ≥ 19 year old Coronary artery disease lesion candidate treatment drug elute stent accord current clinical practice guideline PCI lesion ( ) need stent 26mm Reference diameter 2.25 4.0mm Restenosis lesion Reference vessel diameter &lt; 2.25 mm &gt; 4.0mm Primary PCI STEMI Contraindication antiplatelet agent Treated DES within 3 month vessel Severe hepatic dysfunction ( 3 time normal reference value ) Pregnant woman woman potential childbearing Life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Intravenous ultrasound ,</keyword>
	<keyword>third generation drug-eluting stent</keyword>
</DOC>